Johnson & Johnson: beats consensus in Q4

(CercleFinance.com) - Johnson & Johnson has reported Q4 2018 adjusted net income that is up 12.
5% at 5.4 billion dollars, i.e. 1.97 dollar per share, while analysts were expecting two cents less.

The pharmaceutical group's revenues inched up 1% to 20.4 billion dollars, including a 3.3% increase in operating terms (i.e. excluding FX factors). Excluding changes in the group's consolidation scope as well, revenues increased by 5.3%.

With adjusted EPS of 8.18 dollars and revenues of 81.6 billion dollars for FY 2018, Johnson & Johnson's FY 2019 targets are 8.50 dollars - 8.65 dollars and 80.4 million to 81.2 billion dollars respectively.


Copyright (c) 2019 CercleFinance.com. All rights reserved.